Slides
Page 1
Alembic Pharmaceuticals LimitedInvestor Presentation Q1 FY27
Page 2
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. 2 Safe Harbour StatementThe materials and information presented herein may include forward looking statements , which reflect current expectations, projections, and assumptions. These statements are inherently subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those anticipated.Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product related, forward-looking statements. Product risks and uncertainties include but are not limited to technological advances and patents attained by competitors, challenges inherent in new product development including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trend towards managed care and healthcare cost containment, and governmental laws and regulations affecting domestic and foreign operations.Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to the inability to build production capacity to meet demand, unavailability of raw materials, and failure togain market acceptance.
Page 3
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. 3 Quarterly SnapshotRevenueIndia Branded Business7% YoY growth with quarterly revenues of INR 6.42 billion.US Formulation49% YoY growth, driven by key product launches and volumes.Ex-US Formulation17% YoY growth with continued focus on expanding offerings and strengthening market reachAPI33% YoY growth, supported by a strong order book+23% YoYKey HighlightsEBIDTA before R&DINR 5.23 BnEBIDTA Margin ~24%Revenue INR 21.50 BnR&D 9% of revenue+26% YoY +12% YoYReported PATINR 1.73 Bn Net Profit Margin 8% ProfitabilityPost R&D EBITDA +21% YOYSupported by operating leverage expansion amidst planned strategic expansion in US branded business and R&D pipeline focusing on peptide development and increased filings.+29% YoYEBITDA after R&D 16% of revenue+21% YoY
Page 4
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. 4 Revenue Summary 30%36%18%16%Q1 FY27 India BrandedBusinessUS FormulationEx-US FormulationAPI INR BnQ-o-QQ4 FY26Y-o-YQ1 FY27Q1 FY26BusinessFormulations13%5.687%6.425.99India Branded Business38%5.6449%7.785.23US4%3.6917%3.833.28Ex-US0%3.4733%3.462.61API16%18.4826%21.5017.11Total Revenue
Page 5
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. 5 India Branded Business – Performance19.2620.6322.0023.3924.58 FY22 FY23 FY24 FY25 FY26Revenue TrendCAGR: 6%INR Bn>The India Branded Business recorded 7% growth with revenues of INR 6.41 billion for the quarter.>Alembic is ranked 21stin the Indian Pharmaceutical Market (IPM).>13% of the product portfolio is listed under NLEM.>Sales operations include 5,800+ Medical Representatives across 21 marketing divisions.>Holds a 1.1% market share of the Indian pharma space.*>Five flagship brands have surpassed INR 1 billion in sales.**Source: IQVIA MAT Jun-2619%22%23%21%58%57%Q1FY26 Q1FY27Revenue Q1 FY27Animal HealthAcuteSpeciality 5.996.4215%6%15%14%10%7%11%22%Sales Mix Q1 FY27Anti InfectiveCough & ColdGynecologyCardiologyGastrologyAnti DiabeticOthersAnimal health Growth: 7%
Page 6
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. 6 India Branded Business – Rx Driven RankingsTop Brands with Rank and Market Share * Above market growth is based on the respective molecule group.>Alembic ranks 17th by prescription volume, with a total of 137.6 million prescriptions (MAT Jun 2026). MS% Q1FY 27*Rank Q1FY 27*BRANDS8.82FREEGO10.93WIKORYL5.63ISOFIT6.43BROZEET-LS7.93ULGEL11.23CLOFF4.53VELDROP5.54ETRIK5.84BILAMBIC-M11.04OVIGYN DH3.85TELLZY5.15SHARKOFERROL6.55BLADMIR5.15HARMONISource: IQVIA MAT Jun-26 MS% Q1FY 27*Rank Q1FY 27*BRANDS34.81AZITHRAL31.71CRINA-NCR87.81ALTHROCIN95.11ROXID52.01DELTONE33.91GERIJOINT52.41ELATA6.92CETANIL18.52GESTOFIT SR22.92LACTONIC15.42ESTROPLUS35.12ISOFIT SR19.82TRAVISIGHT13.82UNIGOLIX Driving Overall Prescription Business131.3137.6*Prescriptions (in Mn)MAT Jun-25MAT Jun-260.2370.246*Prescribers (in Mn)Jun-25Jun-26
Page 7
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. 7 11401410Q1FY26 Q1FY27Revenue Q1 FY27Animal Health Business23202806355343055191 FY22 FY23 FY24 FY25 FY26Revenue TrendCAGR: 22%INR MnGrowth: 24%INR Mn INR MnAnnual Sales Value20 - 100100 - 200200 - 300Above 30026536No. of Brands>Alembic operates in the Livestock, Poultry, and Companion Animal segments.>Market leader in Haematinics and Antibiotics with brands such as Sharkoferrol, Moxel , Xceft and Mceft.>The Animal Health division recorded 23% growth in quarter.>A well-established portfolio of strong brands continues to drive growth.34%37%10%10%9%Sales Mix Q1 FY27 Feed Supplement Antibiotic Tonic Supportive TherapyAntiparasitic
Page 8
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. 8 5.237.78 Q1FY26 Q1FY27Revenue Q1 FY27US Business16.6615.7217.319.5722.06FY22 FY23 FY24 FY25 FY26Revenue TrendINR BnGrowth: 49%INR Bn 1643323222Approved ANDAs Oral SolidsDermaOphthalmicInjectableInhalation>Established US front-end with a strong customer base.>7 products launched in Q1 FY27 with a total number of 185 products commercialized as on date.>Pipeline includes 15+ product launches expected in FY27.>Focused on strategically evolving the portfolio and pipeline across complex platforms and specialty segments.>Pivya soft launch completed with encouraging market response; portfolio expansion progressing through the addition of Nuvessa.Total 244** Includes 20 Tentative ApprovalsQ1FY27 : 4 ANDA Filings,10 Approvals.Cumulative : 279 ANDA Filings, 244 approvals and 185 Products Launched so far. CAGR: 7%
Page 9
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. 9 3.283.83Q1FY26 Q1FY27Revenue Q1 FY27Ex-US Business7.758.5210.5212.4314.94 FY22 FY23 FY24 FY25 FY26 Revenue TrendCAGR: 18% INR BnGrowth: 17% INR Bn>Key partnerships active in Europe, Canada, Australia, Brazil, Chile and South Africa.>Achieved 17% YoY growth in Q1 by driving targeted execution, while successfully retaining global business through strong customer demand.>Enhancing global presence through a JV in Canada and new subsidiaries in Thailand, the Philippines, and Germany.
Page 10
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. 10 API Business9.3911.6612.4611.3311.87FY22 FY23 FY24 FY25 FY26 Revenue TrendCAGR: 6% INR BnINR Bn>Achieved a robust 33% YoY growth, reflecting strong market demand, customer confidence, and effective business execution.>3 US DMF filed in Q1 FY27. 152 Cumulative DMF filings with the US FDA.>Continued focus on cost efficiency to remain competitive.2.613.46Q1FY26 Q1FY27Revenue Q1 FY26Growth: 33%
Page 11
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. 11 R&DContinued investment in building product pipelinesR&D CapabilitiesFormulation & API: Vadodara and Hyderabad Bio Centre :VadodaraRising ANDA filings and approvalsChange in total approvals (Final + Tentative) during the FY8.4 7.2 4.8 5.2 7.1 15.8%12.8%7.6%7.8%9.6%FY22 FY23 FY24 FY25 FY26R&D SpendR&D % of sales2320158102124182315FY22 FY23 FY24 FY25 FY26FilingApproval Dosage Form-wise ANDA Approval and Launch – Q1 FY27INR BnR&D Spend Q1-FY’27INR Bn 1.451.861.001.502.002.503.00Q1 FY26 Q1 FY27*Approval Includes 2 Tentative approvals521232 20123456OSD OSD-Onco Injectables Derma*Approval (10)Launched (7)
Page 12
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. 12 Q1 Financials Summary – Profit & Loss statementINR BnParticulars Q-1 FY26 Q-4 FY26 Q-1 FY27 YoY(%) QoQ(%)Revenue from Operations 17.11 18.48 21.50 26% 16%Other Income 0.07 0.26 0.15Total Income 17.17 18.73 21.6526% 16%Material Consumption 4.07 5.32 6.20 52% 17%Employee benefits expense 4.23 4.39 4.74 12% 8%Finance Costs 0.24 0.23 0.28 17% 22%Depreciation & Amortization Expense 0.74 0.89 0.98 32% 10%Other Expenses 5.99 6.49 7.24 21% 12%Total Expenses15.27 17.31 19.43 27% 12%Profit before Share of Profit / (Loss) of Associates 1.91 1.42 2.2116% 56%Share of Profit / (Loss) of Associates & Joint Ventures 0.00 0.01 0.00Profit Before Exceptional 1.90 1.43 2.2217% 55%Exceptional Items - -0.25 - Profit Before Tax 1.90 1.19 2.2217% 87%Tax Expense 0.36 -0.83 0.49Profit for the Period 1.54 2.02 1.7212% -14%Non-controlling interests 0.01 0.01 0.01Profit for the Period attributable to shareholders 1.54 2.03 1.7312% -15%Gross Margin76% 71% 71%EBIDTA Margin before Exceptional17% 14% 16%PBT Margin before Exceptional11% 8% 10%PBT Margin11% 6% 10%PAT Margin9% 11% 8%R&D Expenses as % Revenue8% 11% 9%
Page 13
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. 13 Yearly Financials #Note : FY23 numbers are without considering one-time impact of Aleor write off for better comparison14% #15%16%16%FY23 FY24 FY25 FY26EBIDTA margin %56.5362.2966.7273.45FY23 FY24 FY25 FY26Revenue4.123.455.754.32FY23 FY24 FY25 FY26Capex7.79 #9.6110.5311.77FY23 FY24 FY25 FY26EBIDTA14% *#15%*16% *15%*FY23 FY24 FY25 FY26ROCE %4.97 #6.165.846.75FY23 FY24 FY25 FY26Net ProfitINR Bn * Excluding Assets not deployed & Exceptional Items.
Page 14
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. 14 Sustainability>A l e m b i c ’ s E S G T a r g e t sNet Zero by 2050•63% GHG Emission reduction by 2034•90% GHG Emission reduction by 2050(Approved by SBTi)Water Neutrality by 202750,000 trees by 2027•We are one of the 10 Indian Pharma companies with approved targets under SBTi•Commissioned 24 MW solar park at Bhatpur, Vadodara•20% Reduction in specific water consumption (KL/MT)•81% treated water recycled•Developed 112 recharge wells•Planted 25,000+ trees•16% Reduction in landfill waste•Improved ratings in carbon disclosure projectE n v i r o n m e n t •Zero fatality•Great place to work certification for 3rdconsecutive year•7% increase in safety observations•2,44,460 beneficiaries impacted through CSR InitiativesS o c i a l•Implemented supplier Code of Conduct and the sustainable procurement policy•27% critical vendors assessed against the ESG criteria•Initiated a comprehensive organizational risk assessmentG o v e r n a n c e
Page 15
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. Company Overview
Page 16
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. 16 Company at a GlanceANDA Filings279 (Jun 30,2026)R&D Centers2Manufacturing Facilities9Brands208Field Force5,500+Net Zero Target2050Generics Formulation in the USA185Team Size17,200+MissionImprove Healthcare with innovation, commitment and TrustPrescribers in India2,46,000
Page 17
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. 17 Value Proposition Developing a specialty drug pipeline for IndiaExploring opportunities in InjectablesSupplying APIs to 60+ countries globallyConsistent dividend payoutRanks 21thin the Indian formulations marketEstablished presence in Chile & UAEExpanding product portfolio in the USAStrengthening presence in Canada, South Africa, LATAM & Middle East
Page 18
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. 18 The Journey1907Established by the Amin Family2006FDA-approved API facility2007Acquired Dabur’s Indian Cardiology, GI & Gynecology brands2008FDA-approved Formulation facility2009Multiple divisions to address chronic therapies launched2013Launched first NDA with a partner. Commenced filing in the EU, Australia & Brazil2010Pharmaceutical business demerged from the Alembic Group2015Launched Aripiprazole. Established US front-end transition to direct marketing2012Formed a JV, Rhizen , for NCE Research2016Formed a JV, Aleor , for dermatology portfolio2019Azithral crossed Rs . 250 crore mark as per ORG IMS, MAT Dec 20192022Azithral ranked 16thhighest selling brand. AleorDermaceuticalsmerged with Alembic Pharma2023Started commercialization of products from Injectables and Oncology facilities2025Indore facility Commissioned & Acquired Utility Therapeutics Limited2026• Expanded into the US branded footprint through Alembic Therapeutics.•Formed Canadian JV, for Product Commercialization
Page 19
Investor Presentation Q1 FY27Alembic Pharmaceuticals Ltd. 19 Product brand logo Robust InfrastructureF2 - Panelav F3 - Karkhadi Last USFDA AuditDosage FormLocationInternational GenericsJuly’24General Oral SolidsF1 - PanelavMar’24Oncology Oral SolidsF2 - PanelavOct’24Oncology InjectablesFeb’26*General Injectables & OphthalmicF3 - KarkhadiNov’24General Oral SolidsF4 - JarodMar’23Various derma formsF5 - KarkhadiAPIMay’25API I & II – PanelavMar’25API III - Karkhadi F4 - Jarod F5 - Karkhadi* F3 : EIR received on May 13, 2026. Last WHO AuditDosage FormLocation Mar’26*Oral Solids & LiquidIndia Formulation-Indore* Certification received in Apr’26.
Page 20
2ndFloor, Prime Corporate Park Sahar Road, Andheri East Mumbai 400 099www.alembicpharmaceuticals.com Thank YouFor further queries, please contact:Ms. Isha Lambaisha.lamba@alembic.co.in022-6695 1652Investor Relations AdvisorsAdfactors PR Pvt. Ltd.Snighter Albuquerquesnighter.a@adfactorspr.comDarshan Mankaddarshan.mankad@adfactorspr.com